Glaukos (GKOS) executive Navratil sold 44,436 shares for $10.6M at an average $238.97
Glaukos (GKOS) Chief Development Officer Tomas Navratil sold 44,436 shares for $10.6M at an average price of $238.97 on Oct 30, 2026. He also exercised 12,969 options at $75.97 each, leaving him with 37,328 shares directly held.
How this was made
The 30-second read
Why it matters
The disclosed sale represents a material reduction in insider ownership, which can be interpreted as a negative signal by the market.
Market read
Insider sales of this magnitude often trigger short‑term price declines in biotech stocks, making the filing relevant for traders monitoring GKOS.
What to watch
Navratil's recent option exercise at $75.97 suggests confidence in long‑term upside despite the sale.
Background
Glaukos Corporation (GKOS) is a medical device company focused on ophthalmic treatments. Insider transactions are regularly reported via SEC Form 4.
Ticker impact
SEC Form 4 disclosed that Glaukos CDO Tomas Navratil sold 44,436 shares for $10.6M at $238.97, reducing his stake to 37,328 shares.
likely downward pressure as market prices in the large insider sale
The sale size ($10.6M) is material for a mid‑cap biotech and the insider is a C-level officer; such transactions often precede negative sentiment.
Market effects
May raise concerns for other small‑cap biotech insiders and could prompt scrutiny of Glaukos' pipeline progress.
Limited to US biotech sector, no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
The sale could be a routine liquidity event unrelated to fundamentals; the stock may be undervalued and could rebound.
Key entities
- personTomas Navratil
Chief Development Officer of Glaukos who executed the insider sale.
- companyGlaukos Corporation
US‑listed biotech firm (ticker GKOS) subject of the insider filing.
